Jazz Pharmaceuticals projected its 2026 revenue to reach between $4.60 billion and $4.75 billion while awaiting an August 25 FDA decision on its drug candidate zanidatamab. In August, the company announced the acquisition of Actio Biosciences for $820 million, in a deal potentially worth up to $1.32 billion. This strategic move centers on Actio's lead drug, ABS-1230, which targets rare KCNT1+ epilepsy.
